Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06651281
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohns Disease or Ulcerative Colitis MK-7240-011
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohns Disease or Ulcerative Colitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers want to learn more about tulisokibart also known as MK-7240 in an extension study Tulisokibart is a medicine designed to treat active moderate to severe Crohns disease CD and ulcerative colitis UC An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC called a parent study may be able to join this study The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC and if people tolerate it
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None